Literature DB >> 20087402

Genotype-phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I.

Frank Rauch1, Liljana Lalic, Peter Roughley, Francis H Glorieux.   

Abstract

Osteogenesis imperfecta (OI) is a heritable disorder with bone fragility that is often associated with short stature, tooth abnormalities (dentinogenesis imperfecta), and blue sclera. The most common mutations associated with OI result from the substitution for glycine by another amino acid in the triple helical domain of either the alpha1 or the alpha2 chain of collagen type I. In this study, we compared the results of genotype analysis and clinical examination in 161 OI patients (median age: 13 years) who had glycine mutations in the triple helical domain of alpha1(I) (n=67) or alpha2(I) (n=94). Serine substitutions were the most frequently encountered type of mutation in both chains. Compared with patients with serine substitutions in alpha2(I) (n=40), patients with serine substitutions in alpha1(I) (n=42) on average were shorter (median height z-score -6.0 vs -3.4; P=0.005), indicating that alpha1(I) mutations cause a more severe phenotype. Height correlated with the location of the mutation in the alpha2(I) chain but not in the alpha1(I) chain. Patients with mutations affecting the first 120 amino acids at the amino-terminal end of the collagen type I triple helix had blue sclera but did not have dentinogenesis imperfecta. Among patients from different families sharing the same mutation, about 90 and 75% were concordant for dentinogenesis imperfecta and blue sclera, respectively. These data should be useful to predict disease phenotype in newly diagnosed OI patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087402      PMCID: PMC2987338          DOI: 10.1038/ejhg.2009.242

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  19 in total

Review 1.  Brittle bones--fragile molecules: disorders of collagen gene structure and expression.

Authors:  P H Byers
Journal:  Trends Genet       Date:  1990-09       Impact factor: 11.639

2.  Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV.

Authors:  L M Ward; L Lalic; P J Roughley; F H Glorieux
Journal:  Hum Mutat       Date:  2001-05       Impact factor: 4.878

3.  Natural history of blue sclerae in osteogenesis imperfecta.

Authors:  D Sillence; B Butler; M Latham; K Barlow
Journal:  Am J Med Genet       Date:  1993-01-15

4.  COL1A1 mutation analysis in Lithuanian patients with osteogenesis imperfecta.

Authors:  Egle Benusiené; Vaidutis Kucinskas
Journal:  J Appl Genet       Date:  2003       Impact factor: 3.240

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

Review 6.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

7.  Gly85 to Val substitution in pro alpha 1(I) chain causes mild osteogenesis imperfecta and introduces a susceptibility to protease digestion.

Authors:  M Valli; F Zolezzi; M Mottes; F Antoniazzi; F Stanzial; R Tenni; P Pignatti; G Cetta
Journal:  Eur J Biochem       Date:  1993-10-01

8.  Osteogenesis imperfecta type III with intracranial hemorrhage and brachydactyly associated with mutations in exon 49 of COL1A2.

Authors:  Eissa Faqeih; Peter Roughley; Francis H Glorieux; Frank Rauch
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

Review 9.  Type I procollagen: the gene-protein system that harbors most of the mutations causing osteogenesis imperfecta and probably more common heritable disorders of connective tissue.

Authors:  D J Prockop; C D Constantinou; K E Dombrowski; Y Hojima; K E Kadler; H Kuivaniemi; G Tromp; B E Vogel
Journal:  Am J Med Genet       Date:  1989-09

10.  Osteogenesis imperfecta. The position of substitution for glycine by cysteine in the triple helical domain of the pro alpha 1(I) chains of type I collagen determines the clinical phenotype.

Authors:  B J Starman; D Eyre; H Charbonneau; M Harrylock; M A Weis; L Weiss; J M Graham; P H Byers
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  35 in total

1.  Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study.

Authors:  Keren Machol; Trevor D Hadley; Jake Schmidt; David Cuthbertson; Henri Traboulsi; Rodrigo C Silva; Chloe Citron; Sobiah Khan; Kate Citron; Erin Carter; Kenneth Brookler; Jay R Shapiro; Robert D Steiner; Peter H Byers; Francis H Glorieux; Michaela Durigova; Peter Smith; Michael B Bober; Vernon R Sutton; Brendan H Lee; Sandesh C S Nagamani; Cathleen Raggio
Journal:  Am J Med Genet A       Date:  2019-12-26       Impact factor: 2.802

Review 2.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

Review 3.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

4.  Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta.

Authors:  Katarina Lindahl; Eva Åström; Carl-Johan Rubin; Giedre Grigelioniene; Barbro Malmgren; Östen Ljunggren; Andreas Kindmark
Journal:  Eur J Hum Genet       Date:  2015-05-06       Impact factor: 4.246

5.  Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.

Authors:  Junko Kanno; Akiko Saito-Hakoda; Shigeo Kure; Ikuma Fujiwara
Journal:  J Bone Miner Metab       Date:  2017-05-20       Impact factor: 2.626

6.  Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype.

Authors:  Tim Cundy; Michael Dray; John Delahunt; Jannie Dahl Hald; Bente Langdahl; Chumei Li; Marta Szybowska; Shehla Mohammed; Emma L Duncan; Aideen M McInerney-Leo; Patricia G Wheeler; Paul Roschger; Klaus Klaushofer; Jyoti Rai; MaryAnn Weis; David Eyre; Ulrike Schwarze; Peter H Byers
Journal:  J Bone Miner Res       Date:  2018-04-18       Impact factor: 6.741

7.  Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta.

Authors:  G Bardai; L M Ward; P Trejo; P Moffatt; F H Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2017-04-04       Impact factor: 4.507

8.  Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.

Authors:  Y Liu; D Ma; F Lv; X Xu; J Wang; W Xia; Y Jiang; O Wang; X Xing; W Yu; J Wang; J Sun; L Song; Y Zhu; H Yang; J Wang; M Li
Journal:  Osteoporos Int       Date:  2017-07-19       Impact factor: 4.507

9.  A scoring system for the assessment of clinical severity in osteogenesis imperfecta.

Authors:  Mona S Aglan; Laila Hosny; Rasha El-Houssini; Sawsan Abdelhadi; Fadia Salem; Rokia A S Elbanna; Seham A Awad; Moushira E Zaki; Samia A Temtamy
Journal:  J Child Orthop       Date:  2012-02-08       Impact factor: 1.548

Review 10.  The management of osteoporosis in children.

Authors:  L M Ward; V N Konji; J Ma
Journal:  Osteoporos Int       Date:  2016-04-28       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.